Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open Label, Drug-Drug Interaction, Study to Evaluate the Effect of Itraconazole and Phenytoin on the Pharmacokinetics of ASC41 in Healthy Volunteers and A Study to Evaluate the PK, Safety and Tolerability in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD).

NCT04845646 is registered in ClinicalTrials.gov with Gannex Pharma Co., Ltd. as lead sponsor.

NCT NCT04845646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04845646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open Label, Drug-Drug Interaction, Study to Evaluate the Effect of Itraconazole and Phenytoin on the Pharmacokinetics of ASC41 in Healthy Volunteers and A Study to Evaluate the PK, Safety and Tolerability in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD).
Lead sponsor
Gannex Pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2021
Completion date
June 10, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, nafld